All over the world, the manufacturers of pharmaceuticals are increasingly working and researching with highly potent active pharmaceutical ingredients (HPAPI). This paves the way for new therapies which make it possible to treat patients with lower doses at a simultaneously higher effectiveness of the active ingredients.
As a consequence, the demands on both the product and personnel safety also increase when producing pharmaceuticals. Of the utmost importance here is that the staff are reliably protected against accidental exposure to the active substances. This requirement for operator safety is ensured by means of a suitable containment concept.
Consequently, the big challenge is to unite contradictory requirements in an optimum manner.
Every isolator is designed to meet the following technical aspects:
A complete system from one single supplier brings the advantage of clearly defined interfaces – an important factor in order to achieve the required OEL values.
The use of so-called multi-mill isolator systems makes it possible to produce a large variety of products whose requirements diverge from one another. The universal system concept means that after a mill exchange, the requisite safety level is restored immediately.
To permit integration of the isolator into an existing production process, the process steps both upstream and downstream of the system are taken into consideration and the corresponding interfaces integrated into the isolator. This can be carried out by means of a wide variety of technical solutions: dependent on the batch size or OEL value, there are double butterfly valves, rapid-transfer ports (RTPs) or continuous liner systems available.